Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
IPO Year:
Exchange: NYSE
Website: https://www.elevancehealth.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/18/2024 | $646.00 → $530.00 | Buy → Neutral | BofA Securities |
6/24/2024 | $643.00 | Overweight | Morgan Stanley |
5/30/2024 | $649.00 | Outperform | Robert W. Baird |
3/6/2024 | $584.00 | Overweight | Barclays |
7/12/2023 | Outperform → Peer Perform | Wolfe Research | |
4/27/2023 | $500.00 → $571.00 | Equal-Weight → Overweight | Morgan Stanley |
4/21/2023 | $547.00 | Overweight | Cantor Fitzgerald |
3/28/2023 | $523.00 → $572.00 | Sector Perform → Outperform | RBC Capital Mkts |
9/9/2022 | $535.00 → $575.00 | Neutral → Buy | BofA Securities |
8/22/2022 | $490.00 → $580.00 | Mkt Perform → Outperform | SVB Leerink |
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
10-Q - Elevance Health, Inc. (0001156039) (Filer)
8-K - Elevance Health, Inc. (0001156039) (Filer)
11-K - Elevance Health, Inc. (0001156039) (Filer)
8-K - Elevance Health, Inc. (0001156039) (Filer)
8-K - Elevance Health, Inc. (0001156039) (Filer)
424B3 - Elevance Health, Inc. (0001156039) (Filer)
FWP - Elevance Health, Inc. (0001156039) (Subject)
424B3 - Elevance Health, Inc. (0001156039) (Filer)
8-K - Elevance Health, Inc. (0001156039) (Filer)
DEFA14A - Elevance Health, Inc. (0001156039) (Filer)
Elevance Health's (NYSE:ELV) short percent of float has fallen 4.08% since its last report. The company recently reported that it has 2.19 million shares sold short, which is 0.94% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.45 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interes
Cantor Fitzgerald analyst Sarah James reiterates Elevance Health (NYSE:ELV) with a Overweight and maintains $600 price target.
Wells Fargo analyst Stephen Baxter maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $600 to $593.
TD Cowen analyst Ryan Langston maintains Elevance Health (NYSE:ELV) with a Buy and lowers the price target from $624 to $589.
Wednesday, Elevance Health Inc. (NYSE:ELV) reported second-quarter revenues of $43.2 billion, down 0.4% year-over-year, marginally above the consensus of $43.05 billion. The decrease was driven by attrition in Medicaid membership, partially offset by higher premium yields reflecting the medical cost trend. In the second quarter, UnitedHealth Group Inc (NYSE:UNH) and Elevance Health reported increasing pressure on Medicaid, creating uncertainty about when Medicaid margins will bottom out and when a potential recovery might occur. Centene Inc. (NYSE:CNC), Cigna Corp (NYSE:CI), and Molina Healthcare Inc. (NYSE:MOH) are trading at a 3x lower valuation than Elevance Health. While Elevan
Financial giants have made a conspicuous bearish move on Elevance Health. Our analysis of options history for Elevance Health (NYSE:ELV) revealed 8 unusual trades. Delving into the details, we found 12% of traders were bullish, while 87% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $365,806, and 2 were calls, valued at $245,525. What's The Price Target? Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $500.0 to $670.0 for Elevance Health during the past quarter. Volume & Open Interest Development Examining the volume and open interest provides crucial insights into stock
Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $621 to $611.
RBC Capital analyst Ben Hendrix maintains Elevance Health (NYSE:ELV) with a Outperform and raises the price target from $575 to $585.
B of A Securities analyst Kevin Fischbeck downgrades Elevance Health (NYSE:ELV) from Buy to Neutral and lowers the price target from $646 to $530.
BofA Securities downgraded Elevance Health from Buy to Neutral and set a new price target of $530.00 from $646.00 previously
Morgan Stanley initiated coverage of Elevance Health with a rating of Overweight and set a new price target of $643.00
Robert W. Baird initiated coverage of Elevance Health with a rating of Outperform and set a new price target of $649.00
Barclays initiated coverage of Elevance Health with a rating of Overweight and set a new price target of $584.00
Wolfe Research downgraded Elevance Health from Outperform to Peer Perform
Morgan Stanley upgraded Elevance Health from Equal-Weight to Overweight and set a new price target of $571.00 from $500.00 previously
Cantor Fitzgerald initiated coverage of Elevance Health with a rating of Overweight and set a new price target of $547.00
RBC Capital Mkts upgraded Elevance Health from Sector Perform to Outperform and set a new price target of $572.00 from $523.00 previously
BofA Securities upgraded Elevance Health from Neutral to Buy and set a new price target of $575.00 from $535.00 previously
SVB Leerink upgraded Elevance Health from Mkt Perform to Outperform and set a new price target of $580.00 from $490.00 previously
SC 13G - Elevance Health, Inc. (0001156039) (Subject)
SC 13G - Elevance Health, Inc. (0001156039) (Subject)
SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)
2Q 2024 operating revenue of $43.2 billion 2Q 2024 adjusted operating gain1 of $2.8 billion 2Q 2024 diluted EPS2 of $9.85, up 26%; adjusted diluted EPS1 of $10.12, up 12% 3Q 2024 dividend of $1.63 per share declared to shareholders Elevance Health, Inc. (NYSE:ELV) reported second quarter 2024 results. "Second quarter results reflect the power of our diversified business and thoughtful execution of our strategic initiatives during a dynamic time for our industry, as we remain steadfast in our purpose to improve the health of humanity. We have prudently maintained our full-year outlook and are confident in the earnings power of our Health Benefits and Carelon businesses, which
Elevance Health (NYSE:ELV) will release second quarter 2024 financial results on July 17, 2024, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 800-391-9851 – No Access Code (Domestic Replay) 203-369-3268 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on July 17, 2024, until the end of the day on August 17, 2024. The call w
1Q 2024 operating revenue of $42.3 billion, up 0.9% from 1Q 2023 1Q 2024 diluted EPS1 of $9.59, up 15.5% from 1Q 2023 and adjusted diluted EPS2 of $10.64, up 12.5% FY 2024 diluted EPS and adjusted diluted EPS guidance raised to greater than $34.05 and $37.20, respectively Launching strategic partnership to advance primary care and physician enablement Elevance Health, Inc. (NYSE:ELV) reported first quarter 2024 results. "First quarter results reflect disciplined execution of our strategic initiatives during a dynamic time for our industry. We are making significant progress expanding Carelon's capabilities, scaling our flywheel for enterprise growth, and delivering results fo
Collaboration will leverage the strengths of three care provider entities that will come together to deliver value to consumers and employers across the healthcare journey Elevance Health, Inc. (NYSE:ELV) and Clayton, Dubilier & Rice (CD&R) announced an agreement to form a strategic partnership to accelerate innovation in primary care delivery, enhance the healthcare experience, and improve health outcomes. This effort, which will operate across multiple regions of the United States, will bring together certain care delivery and enablement assets of Elevance Health's Carelon Health and CD&R portfolio companies, apree health and Millennium Physician Group (MPG). "CD&R's collaboration wit
Elevance Health (NYSE:ELV) will release first quarter 2024 financial results on April 18, 2024, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 800-876-4955 – No Access Code (Domestic Replay) 203-369-3997 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on April 18, 2024, until the end of the day on May 17, 2024. The call wil
The JUST 100 is the only ranking that recognizes American corporate leadership on business issues prioritized by the public. Today JUST Capital along with CNBC released its annual JUST 100 list as part of its 2024 Rankings of America's Most JUST Companies. Elevance Health (NYSE:ELV) ranked #8 overall and was recognized for the 6th consecutive year for its commitment to serving its workers, customers, communities, the environment, and shareholders. The JUST 100 are determined by scoring performance across a full range social impact and sustainability criteria and comparing companies head-to-head. The rankings measure how the nation's largest corporations are performing on the business is
4Q 2023 operating revenue of $42.5 billion, up 7.0% from 4Q 2022; FY 2023 operating revenue of $170 billion, up 9.3% from FY 2022 4Q 2023 GAAP diluted EPS1 of $3.63, up 1.1% from 4Q 2022 and adjusted diluted EPS2 of $5.62, up 15.2%; FY 2023 GAAP diluted EPS of $25.22, up 3.9% from FY 2022 and adjusted diluted EPS2 of $33.14, up 16.2% Projected FY 2024 GAAP diluted EPS and adjusted diluted EPS2 of greater than $34.29 and $37.10 per share, respectively Quarterly dividend increased by 10.1% to $1.63 per share Elevance Health, Inc. (NYSE:ELV) reported fourth quarter and full year 2023 results. "We are pleased to have delivered another year of strong performance in 2023, enabled b
Elevance Health (NYSE:ELV) will release fourth quarter and full year 2023 financial results on January 24, 2024 at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 Access Code - 3972058 (Domestic) 312-470-0178 Access Code - 3972058 (International) 800-568-3942 No Access Code (Domestic Replay) 203-369-3812 No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on January 24, 2024 until the end of the day on February 23, 2024
Advances whole health by strengthening Elevance Health's capabilities in multi-site infusion services, specialty pharmacy Elevance Health (NYSE:ELV) today announced that it has entered into an agreement to acquire Paragon Healthcare, Inc., a company specializing in life-saving and life-giving infusible and injectable therapies. For more than 20 years, Paragon Healthcare has provided infusion services to patients through its omnichannel model of ambulatory infusion centers, home infusion pharmacies, and other specialty pharmacy services. The company, headquartered in Plano, Texas, provides high quality and convenient care to patients with a broad range of chronic and acute conditions.
AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a+" (Excellent) of the core Blue Cross Blue Shield-branded insurance subsidiaries of Elevance Health, Inc. (Elevance) (Indianapolis, IN) (NYSE:ELV), as well as its life insurance subsidiaries. These companies collectively are referred to as Anthem Health. At the same time, AM Best has affirmed the Long-Term ICR of "bbb+" (Good), the Long- and Short-Term Issue Credit Ratings (Long-Term IR; Short-Term IR) of Elevance and the Long-Term IR on the existing surplus notes of Anthem Insurance Companies, Inc. (Indianapolis, IN). Concurrently, AM Best has affirmed t
Performant Financial Corporation (NASDAQ:PFMT) (Performant), primarily operating as Performant Healthcare Solutions, a leading provider of technology-enabled payment integrity, eligibility, and related analytics services, is proud to announce the appointment of Dr. Shantanu Agrawal, M.D. to its Board of Directors. Dr. Agrawal brings a wealth of expertise and experience in healthcare policy and payment integrity. As Chief Health Officer at Elevance Health (NYSE:ELV), Dr. Agrawal oversees the whole health strategy, including medical policy and clinical quality, as well as the community health strategy and Elevance Health Foundation. Prior to Elevance Health, Dr. Agrawal held numerous execut
Paragon doubles revenues and increases the number of infusion centers by 400% during Peak Rock's ownership AUSTIN, Texas, Jan. 5, 2024 /PRNewswire/ -- An affiliate of Peak Rock Capital ("Peak Rock"), a leading middle-market private investment firm, announced today it has signed a definitive agreement for the sale of Paragon Healthcare, Inc. ("Paragon" or the "Company") to Elevance Health (NYSE:ELV). Paragon is a leading provider of ambulatory and home infusion services as well as specialty pharmacy services. The Company provides comprehensive, high quality infusion services to patients with chronic health conditions and those in need of post-acute care. Headquartered in Plano, Texas, with m
Mark Kaye named Executive Vice President, Chief Financial Officer Elevance Health (NYSE:ELV) announced today that John Gallina will retire from his role as executive vice president and CFO later this year. Mark Kaye has been named executive vice president and CFO and will serve as a member of the company's executive leadership team, reporting directly to Gail K. Boudreaux, President and CEO. Kaye will serve as CFO Designate from September 6 to November 1, 2023, when he will assume full responsibility for the role. Gallina will remain with Elevance Health serving as Special Advisor to the CEO following his retirement as CFO to ensure a seamless transition. Gallina's distinguished career
Duo Health, a new type of medical group purpose-built to care for patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD) in value-based collaborations with local providers, announced the appointment of Raul Smith as Chief Financial Officer. Smith brings nearly two decades of financial leadership and growth-stage executive experience to the role, where he will lead Duo Health's strategic financial operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230803074729/en/(Photo: Business Wire) Prior to joining Duo Health, Smith served in senior roles at Elevance Health Inc. (NYSE:ELV) including President o
PLANTATION, Fla., Aug. 12, 2022 /PRNewswire/ - Akumin Inc. (NASDAQ:AKU) (TSX:AKU) ("Akumin" or the "Company") provided a business update and announced the termination of employment of its Chief Financial Officer, William Larkin and the appointment of David Kretschmer as Interim Chief Financial Officer, effective today. The Company has implemented a transformation program with initiatives focused on its operations, growth, and capital. These initiatives are intended to support the Company's objectives with respect to patient access and experience, customer and partner engagement, financial sustainability, and employee well-being. The Company is receiving support from a globally recognized tr
Whole Health Index is an industry-leading calculation for defining and measuring the most powerful drivers of individual and community health The Whole Health Index (WHI), created by Elevance Health, Inc. (NYSE:ELV) physicians, data scientists, and researchers, is a first-of-its-kind assessment of health. Using a scale of 0 to 100, the WHI can evaluate a person or group's relative health over time and assess the physical, behavioral, and social factors that influence it. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240802170993/en/Here are a few examples that illustrate how Elevance Health-affiliated plans can use community-
Indianapolis charter school received first ever fitness space, strength training clinics and curriculum Irvington Preparatory Academy today unveiled their first ever weight room and fitness space, provided by Elevance Health in partnership with the Impact Fitness Foundation (IFF), a national nonprofit that provides fitness resources to schools. The facility upgrade marks the third Indianapolis high school to receive a new fitness space in celebration of the Elevance Health Women's Fort Myers Tip-Off, a pre-season collegiate basketball tournament that takes place in November. At Elevance Health, the strategy to become a lifetime trusted health partner is fueled by their purpose to improv
2Q 2024 operating revenue of $43.2 billion 2Q 2024 adjusted operating gain1 of $2.8 billion 2Q 2024 diluted EPS2 of $9.85, up 26%; adjusted diluted EPS1 of $10.12, up 12% 3Q 2024 dividend of $1.63 per share declared to shareholders Elevance Health, Inc. (NYSE:ELV) reported second quarter 2024 results. "Second quarter results reflect the power of our diversified business and thoughtful execution of our strategic initiatives during a dynamic time for our industry, as we remain steadfast in our purpose to improve the health of humanity. We have prudently maintained our full-year outlook and are confident in the earnings power of our Health Benefits and Carelon businesses, which
Elevance Health released its annual Impact Report, highlighting its continued evolution from a traditional health insurance benefits company to a diversified healthcare services organization. The report details significant achievements including the industry-leading Health Equity Accreditation Plus from the National Committee for Quality Assurance, support for Medicaid eligibility renewals, and growth of Carelon. In Elevance Health's ongoing efforts to make a meaningful and healthy impact on communities, its workforce, and the environment, the organization was again included in America's top 50 most community-minded companies and JUST Capital's JUST 100. Elevance Health is especially pr
Elevance Health (NYSE:ELV) will release second quarter 2024 financial results on July 17, 2024, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 800-391-9851 – No Access Code (Domestic Replay) 203-369-3268 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on July 17, 2024, until the end of the day on August 17, 2024. The call w
Elevance Health (NYSE:ELV) announced today that senior management is scheduled to present at Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, Florida on June 12 at 1:20 p.m. Eastern Daylight Time (EDT). All interested parties are invited to listen to a live webcast of the presentation by visiting www.elevancehealth.com and selecting the "Investors" link. You may also access the link here. For those unable to listen to the live webcast, a replay will be available for 90 days following the presentation. To listen to the live webcast, please visit Elevance Health's website www.elevancehealth.com at least 15 minutes early to download and install any necessary audio sof
Elevance Health (NYSE:ELV) announced today that senior management is scheduled to present at Bernstein's 40th Annual Strategic Decisions Conference in New York City, on May 31 at 9:00 a.m. Eastern Daylight Time (EDT). All interested parties are invited to listen to a live webcast of the presentation by visiting www.elevancehealth.com and selecting the "Investors" link. You may also access the link here. For those unable to listen to the live webcast, a replay will be available for 90 days following the presentation. To listen to the live webcast, please visit Elevance Health's website www.elevancehealth.com at least 15 minutes early to download and install any necessary audio software.
Believes Enhabit's Shares Do Not Reflect its Intrinsic Value or Strategic Potential Has Nominated Seven Highly Qualified Independent Directors Believes AREX Slate Would Provide Board With Sorely Needed Home Health and Hospice Expertise NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- AREX Capital Management, LP ("AREX Capital Management" or "we"), together with its affiliates, the owners of approximately 4.8% of the shares of Enhabit, Inc. (NYSE:EHAB) (the "Company" or "Enhabit"), today issued the below statement expressing its disappointment in the conclusion of Enhabit's strategic review. "We are disappointed that Enhabit's strategic review process has concluded without a sale of the Compa
1Q 2024 operating revenue of $42.3 billion, up 0.9% from 1Q 2023 1Q 2024 diluted EPS1 of $9.59, up 15.5% from 1Q 2023 and adjusted diluted EPS2 of $10.64, up 12.5% FY 2024 diluted EPS and adjusted diluted EPS guidance raised to greater than $34.05 and $37.20, respectively Launching strategic partnership to advance primary care and physician enablement Elevance Health, Inc. (NYSE:ELV) reported first quarter 2024 results. "First quarter results reflect disciplined execution of our strategic initiatives during a dynamic time for our industry. We are making significant progress expanding Carelon's capabilities, scaling our flywheel for enterprise growth, and delivering results fo
Collaboration will leverage the strengths of three care provider entities that will come together to deliver value to consumers and employers across the healthcare journey Elevance Health, Inc. (NYSE:ELV) and Clayton, Dubilier & Rice (CD&R) announced an agreement to form a strategic partnership to accelerate innovation in primary care delivery, enhance the healthcare experience, and improve health outcomes. This effort, which will operate across multiple regions of the United States, will bring together certain care delivery and enablement assets of Elevance Health's Carelon Health and CD&R portfolio companies, apree health and Millennium Physician Group (MPG). "CD&R's collaboration wit